Characteristics of patients who were either enrolled with bDMARD/tsDMARD treatment and had interruption(s) during follow-up in the course of which they received csDMARDs alone or who were enrolled with csDMARD treatment and started bDMARD/tsDMARD treatment during follow-up (n=5974)
| Treatment started at enrolment | |||||||
| Monoclonal anti-TNF antibodies | Soluble TNF receptor fusion protein | T cell costimulation modulator | B cell targeted therapy | IL-6 inhibitors | JAK inhibitors | csDMARDs | |
| n=1330 (22.26%) | n=873 (14.61%) | n=395 (6.61%) | n=1296 (21.69%) | n=544 (9.12%) | n=132 (2.21%) | n=1404 (23.50%) | |
| Baseline | |||||||
| Age, mean (SD), years | 55.7 (12.8) | 59.1 (13.2) | 58.3 (13.3) | 58.2 (11.7) | 57.5 (12.7) | 59.9 (12.4) | 56.3 (11.8) |
| Women, n (%) | 1019 (76.6) | 653 (74.8) | 300 (75.9) | 999 (77.1) | 418 (76.8) | 98 (74.2) | 1023 (72.9) |
| DAS28, mean (SD) | 5.0 (1.3) | 5.0 (1.3) | 5.4 (1.3) | 5.3 (1.3) | 5.2 (1.3) | 4.9 (1.3) | 4.6 (1.3) |
| Glucocorticoids, n (%) | 847 (63.7) | 536 (61.5) | 235 (59.6) | 870 (68.0) | 346 (63.7) | 58 (43.9) | 776 (55.3) |
| Glucocorticoids, ≥10 mg, n (%) | 221 (16.7) | 139 (16.0) | 72 (18.3) | 298 (23.4) | 115 (21.2) | 9 (6.9) | 141 (10.0) |
| Follow-up | |||||||
| Duration of treatment episodes, mean (SD), months | |||||||
| Monoclonal anti-TNF antibodies | 12.9 (15.5) | 10.6 (13.0) | 13.0 (15.9) | 12.9 (14.0) | 10.3 (14.0) | 6.2 (6.5) | 15.4 (18.5) |
| Soluble TNF receptor fusion protein | 10.9 (13.0) | 11.8 (14.5) | 9.9 (11.5) | 12.0 (14.8) | 10.0 (11.7) | 6.9 (6.4) | 15.2 (17.2) |
| T cell costimulation modulator | 12.4 (15.8) | 11.0 (11.6) | 12.0 (13.8) | 14.4 (17.3) | 12.6 (17.0) | 6.6 (6.7) | 14.2 (16.3) |
| B cell targeted therapy | 8.6 (8.1) | 8.0 (6.8) | 8.4 (8.3) | 8.2 (7.2) | 8.5 (7.3) | 8.5 (3.2) | 9.3 (11.4) |
| IL-6 inhibitors | 13.1 (15.6) | 12.5 (15.9) | 13.9 (17.2) | 15.0 (18.5) | 13.2 (15.9) | 4.9 (3.3) | 16.5 (18.5) |
| JAK inhibitors | 9.5 (8.5) | 8.5 (8.0) | 8.5 (7.3) | 9.9 (10.1) | 10.7 (9.1) | 7.3 (6.8) | 9.7 (8.5) |
| csDMARDs | 10.1 (14.1) | 9.5 (12.2) | 8.3 (10.9) | 7.4 (10.2) | 8.4 (12.0) | 6.7 (6.7) | 11.7 (14.9) |
bDMARDs, biologic DMARDs; csDMARDs, conventional synthetic DMARDs; DAS28, Disease Activity Score of 28 joints using the erythrocyte sedimentation rate; DMARDs, disease-modifying antirheumatic drugs; IL-6, interleukin 6; JAK, Janus kinase; TNF, tumour necrosis factor; tsDMARDs, targeted synthetic DMARDs.